TruBridge Faces Securities Investigation, Adding Legal Risk to Execution Concerns

What happened

TruBridge, a community-hospital RCM and EHR provider, is now being investigated by Rosen Law Firm for potential securities claims over allegedly misleading disclosures. The company has improved execution with 94% recurring revenue and 19% Adjusted EBITDA margins, but the investigation compounds existing risks: declining bookings, internal control weaknesses, and net debt/EBITDA of 4.65x. Bookings fell to $15.5 million in Q3 2025 from $21 million a year ago, and the stock trades at an EV/EBITDA of 13x—far above a DCF anchor of $4.47 per share. The investigation could distract management, trigger litigation costs, and erode investor confidence in reported numbers. Given the leverage and rich valuation, the legal overhang makes the risk/reward unattractive near term.

Implication

If the claims prove unfounded, TruBridge's operational improvements (high recurring revenue, positive FCF) could still drive value, but the debt burden and competitive pressures limit upside. Deleveraging below 4.0x and clean audit remediation are needed before reconsidering.

Thesis delta

The thesis shifts from an execution-focused WAIT to a more cautious stance, as the securities investigation adds legal and financial liability risks that overshadow near-term operational gains. Previously, the hope was for better entry points on deleveraging; now litigation introduces uncertainty that could delay or impair that recovery.